Almac devises test to detect likelihood of colon cancer recurring
Professor Paul Harkin, President and Managing Director of Almac’s Diagnostic business unit which has devised a new test to detect likelihood of colon cancer recurring. Credit: Almac
The findings of Almac scientists' research have been published in the online version of the Journal of Clinical Oncology (JCO) ahead of the print edition of the journal. The JCO is the peer-reviewed publication of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.
Colon cancer is the third most common cancer in the US. Over 100,000 patients are diagnosed each year and around one quarter of these patients are diagnosed with stage 2 of the disease.
Although the 20% of patients in which the cancer recurs may benefit from chemotherapy there is currently no test which doctors can use to help identify them.
The JCO report gives detail on the development and validation of a prognostic test designed by Almac, ColDX, specifically developed to identify high risk patients who may benefit from additional therapy.
Professor Paul Harkin, President and Managing Director of Almac's Diagnostic business and Professor of Molecular Oncology at Queen's University Belfast said:
"We have used complex technologies designed in Craigavon, Northern Ireland, to examine tumour samples from around the world to identify a genetic signature which tell us the likelihood of stage 2 colon cancer recurring. This technology will make it much more straightforward for doctors to identify high risk patients who may benefit from chemotherapy.
"Our highly novel test represents a significant breakthrough in how colon cancer can be managed. We believe it has the potential to change clinical practice and save the lives of some cancer patients. "Almac is committed to research which improves the health of people around the world and this is just one example of how we are working to achieve that."
Almac scientists including, Professor Richard Kennedy, Dr Max Bylesjo, Dr Peter Kerr, Dr Timothy Davison and Dr Vitali Proutski were involved in the research.
The test was developed using Almac's proprietary discovery technology and using clinical patient samples from around 14 clinical sites across the world including Queen's University Belfast.
Professor Patrick Johnston, Dean, School of Medicine, Dentistry and Biomedical Sciences at Queen's, said:
"We are pleased to have been able to play a role in helping Almac to develop this groundbreaking technology which we hope could save many lives in the future. Both Queen's and Almac are working tirelessly in advancing cancer research and treatments."
Following further external validation and commercialisation the test could be available to UK patients within a couple of years and potentially even sooner in the US.
More information: The full title of the article published in the Journal of Clinical Oncology is entitled: "Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue". jco.ascopubs.org/c… 498.full.pdf
Provided by JPR
- Scientists discover a way to kill off tumors in cancer treatment breakthrough Apr 05, 2011 | not rated yet | 0
- Molecular profiling can accurately predict survival in colon cancer patients Sep 25, 2007 | not rated yet | 0
- Test may help predict colon cancer recurrence risk May 14, 2009 | not rated yet | 0
- Researchers identify gene set that shows which patients benefit from chemo after surgery Sep 07, 2010 | not rated yet | 0
- Gene signature may improve colon cancer treatment Feb 26, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer 22 hours ago | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer 22 hours ago | 5 / 5 (1) | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer May 24, 2013 | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer May 24, 2013 | 5 / 5 (2) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer May 24, 2013 | 5 / 5 (4) | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
3 hours ago | not rated yet | 4
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
22 hours ago | 3.7 / 5 (3) | 3 |
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
3 hours ago | not rated yet | 1
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
19 hours ago | 3 / 5 (2) | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
22 hours ago | 5 / 5 (5) | 0 |
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
3 hours ago | not rated yet | 0